» Articles » PMID: 2469701

Aberrant Phenotypes in Peripheral T Cell Lymphomas

Overview
Journal J Clin Pathol
Specialty Pathology
Date 1989 Apr 1
PMID 2469701
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Seventy six peripheral T cell lymphomas were examined immunohistologically to test their reactivity with a panel of monoclonal antibodies against 11 T cell associated antigens (CD1-8, CD27, UCHL1, and the T cell antigen receptor). Sixty two (82%) lymphomas showed aberrant phenotypes, and four main categories were distinguished as follows: (i) lack of one or several pan-T cell antigens (49, 64% of the cases); (ii) loss of both the CD4 and CD8 antigens (11, 15% of the cases); (iii) coexpression of the CD4 and CD8 antigens (13, 17% of the cases); and (iv) expression of the CD1 antigen (eight, 11% of the cases). No correlation was seen between the occurrence of aberrant phenotypes and the histological subtype. It is concluded that the demonstration of an aberrant phenotype is a valuable supplement to histological assessment in the diagnosis of peripheral T cell lymphomas. It is recommended that the panel of monoclonal antibodies against T cell differentiation antigens should be fairly large, as apparently any antigen may be lost in the process of malignant transformation.

Citing Articles

Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.

Yumeen S, Girardi M Yale J Biol Med. 2020; 93(1):111-121.

PMID: 32226341 PMC: 7087059.


Aberrant phenotypes in Kikuchi's disease.

Wei X, Zhou X, Xie J, Zheng X, Zheng Y Int J Clin Exp Pathol. 2014; 7(9):5557-63.

PMID: 25337197 PMC: 4203168.


Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets.

Piccaluga P, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S J Clin Invest. 2007; 117(3):823-34.

PMID: 17304354 PMC: 1794115. DOI: 10.1172/JCI26833.


A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy.

Washington L, Huh Y, Powers L, Duvic M, Jones D BMC Clin Pathol. 2002; 2(1):5.

PMID: 12475398 PMC: 140025. DOI: 10.1186/1472-6890-2-5.


Hodgkin's lymphoma: the pathologist's viewpoint.

Pileri S, Ascani S, Leoncini L, Sabattini E, Zinzani P, Piccaluga P J Clin Pathol. 2002; 55(3):162-76.

PMID: 11896065 PMC: 1769601. DOI: 10.1136/jcp.55.3.162.


References
1.
Wood G, Burke J, Horning S, Doggett R, Levy R, Warnke R . The immunologic and clinicopathologic heterogeneity of cutaneous lymphomas other than mycosis fungoides. Blood. 1983; 62(2):464-72. View

2.
Cordell J, Falini B, Erber W, Ghosh A, Abdulaziz Z, MacDonald S . Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984; 32(2):219-29. DOI: 10.1177/32.2.6198355. View

3.
Doggett R, Wood G, Horning S, Levy R, DORFMAN R, Bindl J . The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients. Am J Pathol. 1984; 115(2):245-52. PMC: 1900485. View

4.
Weiss L, Crabtree G, Rouse R, Warnke R . Morphologic and immunologic characterization of 50 peripheral T-cell lymphomas. Am J Pathol. 1985; 118(2):316-24. PMC: 1887884. View

5.
Grogan T, Fielder K, Rangel C, Jolley C, Wirt D, Hicks M . Peripheral T-cell lymphoma: aggressive disease with heterogeneous immunotypes. Am J Clin Pathol. 1985; 83(3):279-88. DOI: 10.1093/ajcp/83.3.279. View